We are honored to have Haifeng Bao, CEO of BiOneCure Therapeutics Inc, to speak on the latest MSQ CEO Webinar Series co-hosted by MSQ Ventures and BioAroundWorld. The webinar was moderated by Marc Estigarribia, Managing Director of MSQ Ventures.  

Mr. Bao shared his viewpoints on "Developing Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment." The discussion centered around BiOneCure’s clinical pipeline, value proposition and differentiation, financing milestones, upcoming catalysts, and potential strategic partnering opportunities.

DEVELOPING INNOVATIVE ANTI-DRUG CONJUGATES (ADCS) FOR SOLID TUMOR TREATMENT – BIONECURE THERAPEUTICS

BiOneCure, led by CEO Haifeng Bao, is developing revolutionary antibody-drug conjugates (ADCs) for advanced cancer types. During the presentation, Bao highlighted three distinct payload link platforms - including the Tam platform, the topoisomerase I (Top1) inhibitor platform, and a third platform utilizing a new mode of action toxin.  

The company's impressive pipeline includes several ADC programs targeting novel cancer types and targets. Mr. Bao expertly addressed various important topics during the presentation, including safety measures, combination therapy potential, bystander effects, manufacturing scalability, and the ability to cross the blood-brain barrier. Their lead product, PI-106, designed to treat HER2-positive breast cancer, has shown great promise in Phase 1 clinical trials, particularly for tumor types that may not respond well to other Top1 inhibitor-based ADCs.    

BiOneCure also partners with Nanjing Leads Bio Labs and is actively seeking co-development opportunities with other institutions to tailor groundbreaking ADCs for solid tumor treatments. With successful drug discovery and development experience in the ADC field, BiOneCure's approach to bringing new molecules to the clinical stage could potentially improve the lives of patients with advanced cancers.